Sevenfact

Drug Overview

In the clinical field of hematology, managing patients with complex bleeding disorders requires highly specialized interventions. Sevenfact is a revolutionary medication within the Coagulation Factor VIIa (Recombinant) drug class. It is classified as an advanced BIOLOGIC and a TARGETED THERAPY designed specifically for patients who have developed inhibitors—or neutralizing antibodies—against standard replacement therapies.

Sevenfact is a bypassing agent. This means it can restart the body’s blood-clotting process even when certain parts of the standard clotting “machinery” are broken or blocked by the immune system. Developed through state-of-the-art biotechnology, it provides a reliable option for stopping acute bleeding episodes in individuals whose bodies have rejected traditional Factor VIII or Factor IX treatments.

Generic Name: coagulation factor VIIa (recombinant)-jncw
US Brand Names: Sevenfact
Route of Administration: Intravenous (IV) injection
FDA Approval Status: FDA-approved (April 2020) for use in adults and adolescents 12 years of age and older.

What Is It and How Does It Work? (Mechanism of Action)

In patients with Hemophilia A or B who have developed inhibitors, the immune system produces antibodies that destroy infused Factor VIII or IX before they can work. This creates a blockade in the cascade.

Sevenfact acts as a TARGETED THERAPY by bypassing this blockade. As a recombinant form of activated Factor VII (Factor VIIa), it works at the molecular level through two primary pathways:

Tissue Factor Pathway: Sevenfact binds with Tissue Factor at the site of injury. This complex directly activates Factor X, skipping the need for Factors VIII or IX entirely.
Platelet Surface Activation: At high doses, Sevenfact can activate Factor X directly on the surface of activated platelets.

By stimulating the direct conversion of Factor X to Factor Xa, Sevenfact triggers a “thrombin burst.” This leads to the rapid formation of a stable fibrin clot, providing significant hemorrhage risk reduction even in the presence of high-titer inhibitors.

FDA-Approved Clinical Indications

Primary Indication

Sevenfact is specifically utilized in the hematology category for the treatment and control of bleeding episodes in adults and adolescents (12 years of age and older) with Hemophilia A or B with inhibitors. It is used to manage spontaneous bleeds, such as those in joints or muscles, and traumatic bleeds resulting from injury.

Other Approved & Off-Label Uses

While Sevenfact is currently approved for the treatment of acute bleeds, the class of recombinant Factor VIIa is often used in broader clinical contexts:

Perioperative Management: To prevent and control bleeding during surgical procedures in patients with Hemophilia A or B with inhibitors.
Congenital Factor VII Deficiency: Although not the primary indication for Sevenfact specifically, similar recombinant VIIa agents are the standard of care for this rare deficiency.
Acquired Hemophilia: Management of bleeding in patients who develop spontaneous inhibitors to their own clotting factors.

Dosage and Administration Protocols

Dosing for Sevenfact is strictly weight-based. The medication is provided as a lyophilized (freeze-dried) powder that must be reconstituted with sterile water before intravenous administration.

Bleeding Severity	Initial Dose	Frequency of Repeat Doses
Mild to Moderate Bleed	75 mcg/kg or 225 mcg/kg	Every 3 hours (if using 75 mcg/kg) until hemostasis
Severe Bleed	225 mcg/kg	Every 3 hours until hemostasis is achieved

Important Adjustments:

Dose Timing: If the initial dose is 225 mcg/kg and the bleed is not controlled, a second dose may be administered 9 hours later.
Administration Rate: Sevenfact should be administered as an intravenous bolus injection over a period of 2 minutes.
Renal/Hepatic Insufficiency: There are no specific dose adjustments required for patients with renal or hepatic impairment, though clinical monitoring for thromboembolic events should be heightened in these populations.
Weight-Based Accuracy: For patients weighing over 100 kg, the dose should be calculated based on actual body weight to ensure therapeutic levels are reached.

Clinical Efficacy and Research Results

The efficacy of Sevenfact was established through the PERSEPT (Pharmacokinetics and Efficacy Study in Subjects with Hemophilia A or B with Inhibitors) clinical trial program, which concluded in the early 2020s.

In the PERSEPT 1 trial, which focused on the treatment of mild to moderate bleeding episodes, the results demonstrated that Sevenfact is highly efficacious:

Success Rates: 86.2 percent of bleeding episodes were successfully treated with the 75 mcg/kg dose, and 91 percent were successful with the 225 mcg/kg dose.
Speed of Action: For patients receiving the higher 225 mcg/kg dose, nearly all achieved hemostasis (the stopping of blood) within 9 to 12 hours with a single dose.
Bypassing Reliability: The data confirmed that this BIOLOGIC remains effective regardless of the inhibitor titer (the concentration of antibodies in the blood), providing a consistent response for patients with high-titer inhibitors who fail other treatments.

Safety Profile and Side Effects

Black Box Warning

WARNING: THROMBOEMBOLIC EVENTS. Serious arterial and venous thrombotic events (blood clots) may occur following the administration of Sevenfact. Patients with a history of cardiovascular disease, liver disease, or those receiving concurrent treatments with prothrombin complex concentrates (PCCs) are at an increased risk. Monitoring for signs of blood clots is mandatory.

Common side effects (>10%)

Infusion site reactions (redness, swelling, or pain at the injection site)
Headache
Dizziness
Nausea

Serious adverse events

VTE/Thrombosis Risk: Deep vein thrombosis (DVT), pulmonary embolism, or myocardial infarction.
Cerebrovascular Events: Stroke or TIA.
Hypersensitivity: Severe allergic reactions (anaphylaxis) can occur. Patients allergic to rabbits or rabbit proteins should not use Sevenfact, as the medication is produced in the milk of genetically engineered rabbits.

Management Strategies

If a thromboembolic event is suspected, Sevenfact must be discontinued immediately. Patients should be treated with appropriate anticoagulation therapy as determined by a specialist. In the event of an allergic reaction, stop the infusion and administer emergency protocols (epinephrine, antihistamines).

Research Areas

In the current 2024-2026 research landscape, several novel areas are being explored for Sevenfact and the Factor VIIa class:

Pediatric Use: Ongoing studies are evaluating the safety and efficacy of Sevenfact in children under the age of 12.
Subcutaneous Delivery: Researchers are investigating novel delivery systems to allow Factor VIIa to be given as a simple injection under the skin, which would drastically improve the quality of life for patients.
Combination Therapies: Exploring how Sevenfact interacts with newer non-factor therapies (like bispecific antibodies) to manage breakthrough bleeds.

Patient Management and Practical Recommendations

Pre-treatment Tests

Baseline Coagulation Studies: Prothrombin time (PT) and activated partial thromboplastin time (aPTT). Note that aPTT does not accurately reflect the effectiveness of VIIa, but provides a baseline.
Complete Blood Count (CBC): To monitor platelet counts.
Inhibitor Titer: To confirm the presence of antibodies and guide the use of bypassing agents.

Precautions during treatment

Vigilance for Thrombosis: Monitor for sudden leg swelling, chest pain, shortness of breath, or slurred speech.
Allergy Monitoring: Patients must be observed for signs of hives, wheezing, or low blood pressure, particularly if they have known animal allergies.
Avoid Concurrent PCCs: Do not use activated prothrombin complex concentrates (aPCCs) alongside Sevenfact unless under extreme, supervised clinical necessity, as this exponentially increases clot risk.

“Do’s and Don’ts” List

DO store Sevenfact vials at room temperature (up to 86 degrees Fahrenheit).
DO administer the medication within 4 hours of reconstitution.
DO keep a record of the time, dose, and location of the bleed to share with your hematologist.
DON’T use the medication if you have a known allergy to rabbits or rabbit-derived products.
DON’T shake the vial during reconstitution; gently swirl to avoid foaming.
DON’T use the medication if the solution is cloudy or contains particles.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Coagulation factor therapies carry significant risks of blood clots. Always consult your hematologist or a specialized hemophilia treatment center for diagnosis and treatment plans. If you experience chest pain, sudden weakness, or difficulty breathing, seek emergency medical care immediately.